Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04403139
Other study ID # STUDY00009255
Secondary ID R01AG064800
Status Recruiting
Phase Phase 4
First received
Last updated
Start date April 27, 2022
Est. completion date February 2025

Study information

Verified date May 2024
Source University of Washington
Contact Virology Research Clinic
Phone 206-520-4340
Email vrc@uw.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the effect of intramuscular RZV vaccine on VZV-specific skin TRM and circulating T-cells


Description:

This is an interventional study of vaccination related to infection with varicella zoster virus. We will enroll participants of two age groups. Cohort 1 will be persons between the ages of 30-40; Cohort 2 will be persons who are 70 years of age or older. All participants will receive the FDA-approved recombinant zoster (RZV) vaccine (Shingrix) given at the approved dose and schedule.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date February 2025
Est. primary completion date February 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 30 Years and older
Eligibility Inclusion Criteria: - Cohort 1: 30-40 years of age - Cohort 2: 70 years of age or older - HIV seronegative Exclusion Criteria: - Previous vaccination with Shingrix (RZV), Zostavax (ZVL, zoster vaccine live), or with the chickenpox vaccine - VZV seronegative - Active Hepatitis C infection or active Hepatitis B infection. Persons with serologic evidence of hepatitis C infection that has cleared spontaneously, or with a history of treated hepatitis C with a sustained virologic response, can be enrolled. Persons with a history of resolved hepatitis B infection (negative for hepatitis B surface antigen) can be enrolled - History of a life-threatening allergic reaction (anaphylactic/anaphylactoid reaction) to any component of the vaccine - History of receipt of an organ transplant or hematopoietic stem cell transplant - Significant autoimmune disease such as rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, multiple sclerosis, scleroderma, dermatomyositis, or other condition which in the past has required significant immune modifying medication or which has a clinical course that is characterized by relapses - Has immunosuppression as a result of an underlying illness (e.g. leukemia, lymphoma or other malignant neoplasms) or treatment with immunosuppressive or cytotoxic drugs, or use of anticancer chemotherapy or radiation therapy. - Has long-term use of oral or parenteral steroids (>7 days), or high-dose inhaled steroids (>800 mcg/day of beclomethasone dipropionate or equivalent) within the preceding 6 months (nasal and topical steroids are allowed) - Women of child-bearing potential only: pregnant, breastfeeding, or planning to become pregnant 3 months post vaccination - Has an acute or chronic medical condition that, in the opinion of the investigator, would render biopsies unsafe - History of coagulopathy or taking medication that may cause bleeding (long term high dose aspirin, heparin, coumadin). Aspirin doses <100 mg daily allowed - History of keloid formation or excessive scarring - History of frequent cellulitis or boils (>3 episodes in past 2 years) requiring antibiotic therapy - Allergy to lidocaine, silver nitrate, or mupirocin - Has any condition or medical history that would, in the opinion of the site principal investigator place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Shingrix
All participants will receive the FDA-approved recombinant zoster (RZV) vaccine (Shingrix) given at the approved dose and schedule.

Locations

Country Name City State
United States University of Washington Virology Research Clinic Seattle Washington

Sponsors (2)

Lead Sponsor Collaborator
University of Washington National Institute on Aging (NIA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Level of gE-specific IgG in serum. Units will be optical density at 492 nanometers from ELISA. up to 1 year after vaccination
Primary Level of gE-specific CD4 T cells in blood Units will be cells per million CD4+ T cells in blood. up to 1 year after vaccination
Primary Cytokine profile of gE-specific CD4 T cells in blood Units will be percent of gE-reactive T cells expressing single T cell cytokines or combinations of cytokines up to 1 year after vaccination
See also
  Status Clinical Trial Phase
Completed NCT01682109 - Palatability Testing of a New Paediatric Formulation of Valacyclovir Phase 4
Recruiting NCT05198570 - Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients
Not yet recruiting NCT06409494 - Clinical Trial to Evaluate EuHZV in Healthy Adults Aged 50 to 69 Years Phase 1
Recruiting NCT05532540 - Herpesvirus Immunology in Solid Organ Transplant Recipients - Liver Transplant Study
Recruiting NCT05604911 - Herpes Virus Infections in Kidney Transplant Patients
Not yet recruiting NCT05664152 - An Open-label, Bridging Study of BARYCELA Inj. in Healthy Vietnamese Children Aged Between 12 Months to 12 Years N/A
Completed NCT01689285 - Bioequivalence Study in Healthy Volunteers of a New Paediatric Formulation of Valacyclovir Phase 1
Terminated NCT04081480 - Pharmacokinetics of Valacyclovir Oral Solution in Children N/A